Dan Lu
Impact in
-
- Growth Hormone and Insulin-like Growth Factors
- Hepatology top 10%
- Liver physiology and pathology
Papers in
-
- Glycosylation and Glycoproteins Research 3
- Protein Degradation and Inhibitors 2
- Angiogenesis and VEGF in Cancer 2
- Oncology 5
- CAR-T cell therapy research 2
- Co-authors
- Zhenping Zhu (5 shared papers)Dale L. Ludwig (4 shared papers)Xenia Jimenez (3 shared papers)Larry Witte (3 shared papers)Rajiv Bassi (3 shared papers)Daniel J. Hicklin (3 shared papers)Marie Prewett (2 shared papers)Daniel S. Pereira (2 shared papers)
- Journals
- Molecular Therapy (1 paper)Molecular Cancer Therapeutics (1 paper)Blood (1 paper)Vaccine (1 paper)BMC Cancer (1 paper)
- Partner nations
- ChinaUnited StatesMacao
In The Last Decade
Dan Lu
14 papers receiving 664 citations
Peers
Comparison fields: 5 of 62
- Endocrinology, Diabetes and Metabolism 183
- Hepatology 70
- Cancer Research 131
- Oncology 203
- Molecular Biology 458
Countries citing papers authored by Dan Lu
This map shows the geographic impact of Dan Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Lu more than expected).
Fields of papers citing papers by Dan Lu
This network shows the impact of papers produced by Dan Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Lu. The network helps show where Dan Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Dan Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. | 2003 | 298 |
| 2 | 2006 | 105 | |
| 3 | 2006 | 79 | |
| 4 | 2005 | 47 | |
| 5 | 2004 | 42 | |
| 6 | 2009 | 32 | |
| 7 | 2018 | 32 | |
| 8 | 2012 | 30 | |
| 9 | 2013 | 10 | |
| 10 | 2022 | 8 | |
| 11 | 2020 | 5 | |
| 12 | 2017 | 4 | |
| 13 | 2025 | 1 | |
| 14 | 2025 | 1 | |
| 15 | 2025 | 0 | |
| 16 | 2025 | 0 |
About Dan Lu
Dan Lu is a scholar working on Molecular Biology, Oncology, Immunology, Epidemiology and Genetics, having authored 16 papers that have together received 694 indexed citations. Recurring topics across this work include Glycosylation and Glycoproteins Research (3 papers), Protein Degradation and Inhibitors (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), CAR-T cell therapy research (2 papers), Hepatitis B Virus Studies (2 papers), Immune Cell Function and Interaction (2 papers), Angiogenesis and VEGF in Cancer (2 papers) and Neuroblastoma Research and Treatments (1 paper). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (183 citations), Hepatology (70 citations), Cancer Research (131 citations), Oncology (203 citations) and Molecular Biology (458 citations). Dan Lu has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Zhenping Zhu, Dale L. Ludwig, Xenia Jimenez, Larry Witte, Rajiv Bassi, Daniel J. Hicklin, Marie Prewett, Daniel S. Pereira, Paul Kussie and Peter Böhlen. Their work appears in journals such as Molecular Therapy, Molecular Cancer Therapeutics, Blood, Vaccine and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.